Market closed
Metagenomi/$MGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Metagenomi
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
Ticker
$MGX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
202
Website
Metagenomi Metrics
BasicAdvanced
$59M
-
-$2.36
-
-
Price and volume
Market cap
$59M
52-week high
$8.86
52-week low
$1.23
Average daily volume
401K
Financial strength
Current ratio
6.914
Quick ratio
6.732
Long term debt to equity
17.111
Total debt to equity
19.492
Management effectiveness
Return on assets (TTM)
-16.12%
Return on equity (TTM)
-34.69%
Valuation
Price to revenue (TTM)
0.992
Price to book
0.25
Price to tangible book (TTM)
0.25
Price to free cash flow (TTM)
-0.462
Growth
Revenue change (TTM)
16.84%
Earnings per share change (TTM)
-88.21%
3-year revenue growth (CAGR)
499.26%
3-year earnings per share growth (CAGR)
-14.40%
What the Analysts think about Metagenomi
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Metagenomi stock.
Metagenomi Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Metagenomi Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Metagenomi News
AllArticlesVideos
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
GlobeNewsWire·1 month ago
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
GlobeNewsWire·1 month ago
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Metagenomi stock?
Metagenomi (MGX) has a market cap of $59M as of April 17, 2025.
What is the P/E ratio for Metagenomi stock?
The price to earnings (P/E) ratio for Metagenomi (MGX) stock is 0 as of April 17, 2025.
Does Metagenomi stock pay dividends?
No, Metagenomi (MGX) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Metagenomi dividend payment date?
Metagenomi (MGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Metagenomi?
Metagenomi (MGX) does not currently have a Beta indicator.